-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Benzinga·04/09/2025 11:38:33
Listen to the news
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.